Abstract Aims/hypothesis: Partitioning-defective protein-6α (Par6α) has recently been demonstrated to negatively regulate insulin signalling in murine myoblasts. To address whether Par6α plays a role in human physiology, the present study investigated whether mutations exist in the Par6α gene and whether these mutations, if present, are associated with pre-diabetic phenotypes in non-diabetic subjects. Methods: The complete gene (part of the promoter [2.1 kb], all exons/introns and the 3′ untranslated region) encoding Par6α was analysed in 664 non-diabetic subjects. We investigated possible associations between single nucleotide polymorphisms and percentage of body fat, glucose tolerance (as determined by OGTT), serum NEFA concentrations and whole-body insulin sensitivity (estimated during the OGTT, and for a subgroup of 242 subjects determined by the euglycaemic-hyperinsulinaemic clamp). Results: A rare A/G polymorphism was found 336-bp upstream of the translational start codon (allele frequency 0.03). The data for subjects homozygous and heterozygous for −336G (R/G, n=43) were combined and compared with those for subjects homozygous for −336A (A/A, n=621). Subjects with the R/G genotype had lower fasting (4.84± 0.09 mmol/l, means±SEM, p=0.049) and 2-h (5.50±0.02 mmol/l, p=0.050) plasma glucose concentrations than subjects with the A/A genotype (5.02±0.02 and 5.94±0.06 mmol/l, respectively). Subjects with the R/G genotype also had lower fasting (448±31 μmol/l, p=0.018) and 2-h serum NEFA concentrations (61±7 μmol/l, p= 0.015) than subjects with the A/A genotype (529±9 and 75± 2 μmol/l, respectively), adjusted for age, sex and percentage of body fat. There were no differences in adiposity or whole-body insulin sensitivity between the two genotype groups (all p> 0.36). A luciferase reporter gene assay revealed that the −336G promoter variant had a significantly lower (−22.8%, p=0.006) transcriptional activity in transfected C2C12 murine myoblasts than the −336A promoter variant. Conclusions/interpretation: A novel functional variant in the promoter of the Par6α gene is associated with reduced fasting glycaemia, increased glucose tolerance and reduced serum NEFA concentrations.
Introduction
The pathogenesis of type 2 diabetes involves a combined defect in insulin secretion and insulin action [1] . The atypical isoforms of protein kinase C (aPKCs) play important roles in the modulation of insulin action. These serine/ threonine kinases have been shown to be positively involved in the transport of glucose in fat and muscle in various cell lines and animal models [2] . However, aPKCs also exert a negative regulatory function on insulin action. Firstly, aPKCs are able to phosphorylate insulin receptor substrate-1 (IRS-1) on serine residues, thereby downregulating the recruitment and activation of phosphatidylinositol-3-kinase (PI3K) by IRS-1, especially under prolonged stimulation with insulin [3] [4] [5] . Secondly, when stimulated with ceramide, aPKCs directly inhibit protein kinase B(α) [6] , one of the key molecules required for insulin-dependent glucose transport and glycogen synthesis [7, 8] .
Both aPKC-dependent inhibitory mechanisms may be involved in the pathogenesis of type 2 diabetes. Thus, it is important to understand how aPKCs are regulated in insulin signalling.
Several aPKC-interacting proteins influence aPKC activity and substrate specificity [9] , including the partitioning-defective protein-6 (Par6) family, which comprises three isoforms (α, β and γ). Par6 activates the aPKCs via an unknown mechanism and plays an important role in asymmetric cell division and cell polarisation [10, 11] . Par6 has also been shown to play a role in insulin signalling in 3T3L1 adipocytes [12] . We have recently demonstrated that the α isoform of Par6 (Par6α) is expressed in human insulinsensitive tissues (liver, brain, muscle, pancreas) and that overexpressed Par6α enhances the negative effect of the aPKCs on insulin action in C2C12 murine myoblasts [13] . However, little is known about the effects of Par6α on insulin sensitivity in humans. In the present study we therefore investigated whether mutations exist in the human gene encoding Par6α and whether these mutations, if present, are associated with pre-diabetic phenotypes in a nondiabetic population.
Subjects and methods
Subjects We analysed data on 664 subjects with normal or impaired glucose tolerance [14] who participated in the Tübingen Family Study of type 2 diabetes. The participants were not receiving any medication known to affect glucose tolerance or insulin sensitivity. Of the total study population, 242 underwent a euglycaemic-hyperinsulinaemic clamp. Tests were performed at 0800 h after an overnight fast of 10 h. Subjects were asked to refrain from smoking over the same period. Informed written consent was obtained from all participants and the protocol was approved by the local medical ethics committee. The characteristics of the subjects are shown in Table 1 .
Body composition and body fat distribution Body composition was measured by bioelectrical impedance as percentage of body fat. BMI was calculated as weight divided by the square of height (kg/m 2 ). Waist and hip circumferences were measured with subjects in the supine position, and the WHR was calculated as an index of the distribution of body fat.
Oral glucose tolerance test All subjects underwent an OGTT [15] . After an overnight fast, subjects ingested a solution containing 75 g of dextrose, and venous blood samples were obtained at 0, 30, 60, 90 and 120 min for determination of plasma glucose concentrations. Insulin sensitivity was calculated from the glucose and insulin concentrations measured during the OGTT using the formula proposed by Matsuda and DeFronzo [16] . Serum NEFA concentrations were measured at 0 and 120 min.
Whole-body insulin sensitivity At approximately 0800 h, an antecubital vein was cannulated for infusion of insulin and glucose. A dorsal hand vein of the contralateral arm was cannulated and placed under a heating device to permit sampling of arterialised blood. After basal blood was drawn, subjects received a primed insulin infusion at a 27rate of 1.0 mU·kg −1 ·min −1 for 2 h. Blood was drawn every 5 min for the determination of blood glucose, and a glucose infusion was adjusted such that fasting glucose levels were maintained. An insulin sensitivity index (in μmol·kg
) for systemic glucose uptake was calculated as the mean infusion rate of glucose (in μmol·kg
) necessary to maintain euglycaemia during the last 60 min of the euglycaemic-hyperinsulinaemic clamp divided by the steady-state serum insulin concentration.
Analytical procedures Blood glucose was determined by the glucose oxidase method using a bedside glucose analyser (YSI Blood Glucose Analyzer; Yellow Springs Instruments, Yellow Springs, CO, USA). Plasma insulin was determined by microparticle enzyme immunoassay (Abbott Laboratories, Tokyo, Japan). Serum NEFA concentrations were determined using an enzymatic method (WAKO Chemicals, Neuss, Germany).
Genotyping Genomic DNA was isolated from whole blood using a commercial DNA isolation kit (NucleoSpin; Macherey-Nagel, Düren, Germany). Oligonucleotide primers were designed in order to amplify the gene encoding Par6α. Use of these primers revealed amplification products of approximately 400 bp. By 14 overlapping reactions, the complete gene (part of the promoter [2.1 kb], all exons/introns and the 3′ untranslated region) was amplified by PCR in a screen of 50 subjects (Fig. 1 ). The PCR products were then sequenced bidirectionally using an ABI Prism dye terminator cycle sequencing ready reaction kit (Applied Biosystems, Foster City, CA, USA) and an ABI Prism 310 automated sequencer (Applied Biosystems). Genotyping of the newly detected single nucleotide polymorphism (SNP) was achieved using the TaqMan assay (Applied Biosystems). The TaqMan genotyping reaction was amplified using a GeneAmp PCR system 7000 (95°C for 10 min, then 38 cycles at 95°C for 15 s, 62°C for 1 min), and fluorescence was detected using an ABI Prism 7000 sequence detector (Applied Biosystems). As a quality standard, we randomly included six positive (2×A/A, 2×A/G, 2×G/G) and two negative (all components excluding DNA) sequenced controls in each TaqMan reader plate. Because all controls were correctly identified, we assumed that the genotyping error rate of this method did not exceed 0.3%, as demonstrated previously in a study designed to validate this method [17] .
Reporter gene assay A promoter region of the human Par6α gene comprising nucleotides −1253 to +109 (position relative to the translational start codon) was amplified from the genomic DNA of a heterozygous −336A/G subject using the forward primer 5′-CTTCTCCTCCCTGCAACA AG-3′ and the reverse primer 5′-AAGAGGGAATTGGGA GCG-3′. The fragment was subcloned into the pCR-Blunt vector (Invitrogen, Carlsbad, CA, USA). Clones containing the −336A or the −336G variant of the promoter were identified by sequencing. Both promoter fragments were obtained by restriction with EcoRI (New England Biolabs, Beverly, MA, USA), were blunted with a Klenow fill-in and were inserted into pGL3(R2.1) Basic Vector (Promega, Madison, WI, USA) containing the firefly luciferase reporter gene, which was cleaved using SmaI. After confirmation of correct orientation, pGL3(R2.1) Basic Vectors containing the Par6α gene promoter variants and a positive control vector containing the Renilla reniformis luciferase under the control of the Herpes simplex virus thymidine kinase (pRL-TK; Promega) were cotransfected at a ratio of 3:1 into C2C12 cells cultured with DMEM+10% FCS+2 mmol/l glutamine. After 48 h, cells were washed with PBS and extracted into the lysis buffer provided with the Dual Luciferase Reporter Assay System (Promega). Firefly luciferase activity was measured according to the manufacturer's protocol with a Magic Lite Analyzer (Ciba Corning, Essex, UK) and was normalised to the corresponding Renilla luciferase activity. Each transfection was performed 16 times.
Statistical analyses Unless stated otherwise, data are provided as means±SEM. Statistical comparison of genotype groups was performed using logarithmically transformed data (for non-normally distributed parameters). Multivariate linear regression analyses were performed to adjust for the effects of relevant covariates (age, sex, percentage of body fat). A p value less than or equal to 0.05 was considered to be statistically significant. The analyses were conducted using the JMP statistical software package (SAS Adjusted fasting glucose (mmol/l, log)
Adjusted 2-h glucose (mmol/l, log) Institute, Cary, NC, USA) or SPSS software (SPSS, Chicago, IL, USA).
Results
We screened 50 subjects who participated in the Tübingen Family Study of type 2 diabetes. Previously reported SNPs in the Par6α gene (three in the promoter region, one in exon 1, three in the 3′ untranslated region), which are listed in the dbSNP database (http://www.ncbi.nlm.nih.gov/SNP, last accessed in January 2005), were not detected in our population. However, a novel SNP (A/G) was detected 336-bp upstream of the translational start codon. Interestingly, using the GenScan software [18] , we found that the SNP was located within a 40-bp region (−340 to −300) predicted to function as a promoter for the Par6α gene (Fig. 1) . The allelic frequency of this rare SNP was 0.03 in our population. Genotype frequencies were in Hardy-Weinberg equilibrium (p=0.34 according to the Chi square test). For statistical analysis, the results for subjects homozygous (n=2) and heterozygous (n=41) for the −336G allele were combined (R/G, n=43) and compared with those of subjects homozygous for the −336A allele (A/A, n=621) ( Table 1) . There were no differences between the two groups with respect to age, sex, body fat distribution or adiposity. However, subjects with the R/G genotype had lower fasting (4.84±0.09 mmol/l, p=0.049) and 2-h (5.50±0.02 mmol/l, p=0.050) plasma glucose concentrations compared with subjects with the A/A genotype (5.02±0.02 and 5.94±0.06 mmol/l, respectively) (Fig. 2) . Subjects with the R/G genotype also had lower fasting (448±31 μmol/l, p=0.018) and 2-h (61±7 μmol/l, p=0.015) serum NEFA concentrations compared with subjects with the A/A genotype (529±9 and 75±2 μmol/l, respectively) (Fig. 3) , after adjustment for age, sex and percentage of body fat. There were no differences between the two groups in terms of insulinaemia or whole-body insulin sensitivity as determined during the OGTT and/or the euglycaemic-hyperinsulinaemic clamp (both p>0.36; Table 1 ). Furthermore, genotype was not associated with serum triglycerides or total, HDL or LDL cholesterol levels (n=644, all p>0.29; data not shown). The Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 gene (PPARγ2) is a genetic variant that influences the sensitivity of lipolysis to insulin [19] . We investigated whether the effects of the −336A/G polymorphism in the Par6α gene on serum NEFA concentrations were similar to those observed for the Pro12Ala variant by comparing serum NEFA concentrations in a subgroup of the study population that was genotyped for both genetic variants (n=629; data not shown). The Pro12Ala polymorphism was associated with 9% lower fasting serum NEFA concentrations and 12% lower 2-h serum NEFA concentrations. These effects were comparable to those observed for the −336A/G polymorphism of the Par6α gene in this subgroup (13 and 11%, respectively). We also found that the effects of the −336A/G polymorphism on serum NEFA concentrations (basal and 2 h) were independent of the Pro12Ala variant of the PPARγ2 gene (both p=0.057 according to general linear Fig. 4 Comparison of promoter activity with either A or G at position −336. Promoter activity was assayed with the dual luciferase assay in transiently transfected C2C12 murine myoblasts. The mean ratio of firefly:Renilla luciferase activity of the wild-type promoter construct (−336A) is shown as 100% relative activity. Data were obtained from 16 independent experiments and are expressed as means+SEM. * p=0.006 using an unpaired Student's t-test Adjusted fasting NEFA (µmol/l, log) To investigate whether the newly detected SNP in the promoter of the Par6α gene influences the transcription of the gene, we tested both promoter variants in a reporter gene assay. After normalisation of luciferase activities to the corresponding transfection efficiencies, a significantly lower (−22.8%, p=0.006) transcriptional rate was observed in C2C12 cells expressing the −336G promoter construct compared with cells expressing the wild-type promoter of the Par6α gene (n=16; Fig. 4) .
Discussion
This is the first report on the associations between genetic variations in the Par6α gene and pre-diabetic phenotypes. The results presented in this paper strengthen the hypothesis that Par6α may play a role in glucose and lipid metabolism in humans. Due to the observed associations between the polymorphism and fasting glucose and glucose tolerance, we expected the SNP to have an effect on whole-body insulin sensitivity as determined during the OGTT and the euglycaemic-hyperinsulinaemic clamp. However, whole-body insulin sensitivity was not found to be different between genotypes. At first glance, this finding implies that the SNP in the promoter of the Par6α gene may not be important in liver and muscle, the main tissues influencing whole-body insulin sensitivity. Nevertheless, it may be speculated that Par6α specifically plays a role in liver. The results of a previous study suggest that basal and 2-h glycaemia are largely influenced by basal and insulinsuppressed hepatic glucose production, both of which are measurements of hepatic insulin sensitivity [20] . However, it has also been shown that IGT primarily results from the reduced suppression of hepatic glucose output due to abnormal pancreatic islet function [21] . In the present study, hepatic insulin sensitivity was not directly determined; hence, further investigations are warranted to clarify this issue.
In addition to the association with glycaemia, we found that the polymorphism affected fasting and 2-h NEFA concentrations. Both basal and post-load NEFA concentrations are indirect measurements of the insulin sensitivity of lipolysis. Thus, it can be speculated that these results indicate a role for Par6α in the regulation of lipolysis. It appears possible that the decreased release of NEFAs would permit the liver to suppress glucose production more efficiently under basal and insulin-stimulated conditions. To date, high levels of expression of human Par6α have only been verified in adult insulin-sensitive tissues, such as brain, liver, pancreas and skeletal muscle [22] [23] [24] . We have also recently demonstrated Par6α expression in the visceral adipose tissue of C57Bl6 mice (unpublished observation). This finding further supports a role for Par6α in adipose tissue lipid metabolism. Our subgroup analysis of subjects genotyped for both the Pro12Ala and −336A/G polymorphisms revealed that the SNP in the Par6α gene was associated with reductions in fasting and 2-h NEFA concentrations that were similar to those observed for the Pro12Ala variant; this effect still tended to be significant after adjustment for the latter. Thus, although the SNP in the Par6α gene has a much lower allelic frequency than the Pro12Ala variant, it has a similar effect on serum NEFA concentrations. Nevertheless, the −336A/G polymorphism probably does not account for a large part of the variability in fasting and 2-h glucose concentrations observed in this study. Whether it is more important in other populations needs to be determined.
The SNP described in this paper is located in a 40-bp region that was predicted to represent the promoter for the Par6α gene by the GenScan software, which provides a reliable algorithm for the identification of promoter elements and genes [18] . Analysis of this promoter sequence using the TRANSFAC database (http://www.gene-regulation.com/ pub/databases.html#transfac, last accessed in January 2005) [25] revealed that it contains a protein-binding motif (GG AAAT) previously detected in the promoter of the human insulin gene by a DNAse-footprinting assay [26] . This GG AAAT motif is changed to GGAAGT by the −336A/G SNP. It may therefore be surmised that the SNP influences the binding affinity of an as yet unknown transcription factor that possibly regulates the transcription of the Par6α gene. Interestingly, the data we obtained from the reporter gene assay in C2C12 cells confirmed that the −336G promoter variant resulted in a significantly lower transcriptional activity compared with the −336A variant. The finding that Par6α negatively regulates insulin signalling in C2C12 cells [13] supports the hypothesis that the decreased expression of Par6α may account for the effects observed in SNP carriers.
In conclusion, this is the first report to show that a functional variant in the promoter of the Par6α gene is correlated with glycaemia and serum NEFA concentrations in humans. These data support our hypothesis that the Par6α gene represents a candidate gene for type 2 diabetes.
